Yderligere hændelser, som forekom hyppigere hos de patienter, der blev behandlet med sitagliptin (uden at nå 5% niveauet, men med en incidens > 0, 5%, der er højere i sitagliptin - end i kontrolgruppen) omfatter osteoartritis og smerter i ekstremiteterne.
Additional adverse events that occurred more frequently in patients treated with sitagliptin (not reaching the 5% level, but occurring with an incidence of > 0.5% higher with sitagliptin than that in the control group) included osteoarthritis and pain in extremity.